Clinical factors | Center A (n = 395) | Training Set (n = 281) | Internal validation Set (n = 114) | P* value | Center B External validation Set (n = 52) | P# value |
---|---|---|---|---|---|---|
Age (years) | 60.0(53.0; 67.0) | 59.0(53.0; 67.0) | 60.0(51.2; 65.0) | 0.211 | 58(49; 69.3) | 0.377 |
Tumor-size (cm) | 4.0 (2.9; 5.5) | 4.1 (2.8; 5.5) | 3.9 (3.1; 5.3) | 0.980 | 3.5 (2.5;4.9) | 0.084 |
Sex | Â | Â | Â | 0.001* | Â | 0.203 |
Female | 130(32.9) | 107 (38.1) | 23 (20.2) | Â | 12 (23.1) | Â |
Male | 265 (67.1) | 174 (61.9) | 91 (79.8) | Â | 40 (76.9) | Â |
ISUP grade | Â | Â | Â | 0.926 | Â | 0.168 |
I | 14 (3.5) | 11 (3.9) | 3 (2.6) | Â | 3 (5.8) | Â |
II | 314 (79.5) | 223 (79.4) | 91 (79.9) | Â | 44 (84.6) | Â |
III | 58 (14.7) | 41 (14.6) | 17 (14.9) | Â | 3 (5.8) | Â |
IV | 9 (2.3) | 6 (2.1) | 3 (2.6) | Â | 2 (3.8) | Â |
T stage | Â | Â | Â | 0.08 | Â | 0.574 |
T1 | 323 (81.8) | 234 (83.3) | 89 (78.0) | Â | 46 (88.4) | Â |
T2 | 42 (10.6) | 31 (11.0) | 11 (9.7) | Â | 3 (5.8) | Â |
T3 | 30 (7.6) | 16 (5.7) | 14 (12.3) | Â | 3 (5.8) | Â |
N stage | Â | Â | Â | 0.494 | Â | 1.000 |
N0/x | 393 (99.5) | 280 (99.6) | 113 (99.1) | Â | 52 (100) | Â |
N1 | 2 (0.5) | 1 (0.4) | 1 (0.9) | Â | 0 (0) | Â |
Tumor Necrosis | Â | Â | Â | 0.417 | Â | 0.785 |
Absent | 362 (91.6) | 255 (90.7) | 107 (93.9) | Â | 49 (94.2) | Â |
Present | 33 (8.4) | 26 (9.3) | 7 (6.1) | Â | 3 (5.8) | Â |
Nephrectomy type | Â | Â | Â | 0.787 | Â | 0.463 |
Radical | 238 (60.3) | 171 (60.9) | 67 (58.8) | Â | 28 (53.9) | Â |
Patial | 157 (39.7) | 110 (39.1) | 47 (41.2) | Â | 24 (46.1) | Â |
ECOG-PS | Â | Â | Â | Â | Â | 0.166 |
0 score | 341 (86.3) | 239 (85.1) | 102 (89.5) | 0.319 | 49 (94.2) | Â |
> 0 score | 54 (13.7) | 42 (14.9) | 12 (10.5) |  | 3 (5.8) |  |
Recurrence | Â | Â | Â | 0.808 | Â | 1.000 |
Absent | 354 (89.6) | 253 (89.1) | 101 (88.6) | Â | 47 (90.4) | Â |
Present | 41 (10.4) | 28 (9.96) | 13 (11.4) | Â | 5 (9.6) | Â |
Follow-up time | 48.1(34.9; 63.1) | 48.1(35.0; 63.1) | 48.0(34.7; 64.4) | 0.967 | 28.5(20.0;44.0) | < 0.001 |